Patent · US Active

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

US11066361B2 · kind B2 · utility

0Cited by

37References

3Claims

0Family size

Assignee

CAYMAN CHEMICAL COMPANY, INC. · US

Inventors

Stephen Douglas Barrett · Hartland, US
Fred Lawrence Ciske · Dexter, US
Joseph Michael Colombo · Ann Arbor, US
Gregory William Endres · Saline, US
Bradlee David Germain · Ann Arbor, US
Andriy Kornilov · Ypsilanti, US
James Bernard Kramer · Sylvania, US
Adam Uzieblo · Farmington Hills, US
Kirk M. Maxey · Ann Arbor, US

Key dates

Filing date	Jan 2, 2020
Grant date	Jul 20, 2021
Priority date	—
Expiry date	Jan 2, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61L2430/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.